Definium Therapeutics, Inc. has entered into an underwriting agreement for a public offering of its common shares, expecting to raise approximately $758 million in net proceeds. The offering includes the full exercise of the underwriters' option to purchase additional shares.
Key Details
- Offering Details: A total of 23,676,471 common shares were offered at a price of $34.00 per share, which includes 3,088,235 shares from the full exercise of the underwriters' option on June 24, 2026.
- Financial Impact: The company expects gross proceeds of approximately $805 million and net proceeds of approximately $758 million after deducting underwriting discounts and other expenses.
- Use of Proceeds: Net proceeds are intended for research and development of product candidates, preparation for potential commercialization of DT120 ODT (if approved), and for general corporate purposes.
- Timeline & Parties: The agreement was entered into on June 23, 2026, with the offering expected to close on June 25, 2026. Underwriters are represented by J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities.